Aveo Pharmaceuticals Inc (NASDAQ:AVEO): Institutional Investors Are Worried

June 18, 2018 - By Christine McCrea

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Logo

Sentiment for Aveo Pharmaceuticals Inc (NASDAQ:AVEO)

Aveo Pharmaceuticals Inc (NASDAQ:AVEO) institutional sentiment decreased to 1.24 in Q1 2018. Its down -1.57, from 2.81 in 2017Q4. The ratio fall, as 36 institutional investors increased and started new stock positions, while 29 sold and decreased their positions in Aveo Pharmaceuticals Inc. The institutional investors in our partner’s database now possess: 57.68 million shares, down from 59.55 million shares in 2017Q4. Also, the number of institutional investors holding Aveo Pharmaceuticals Inc in their top 10 stock positions was flat from 1 to 1 for the same number . Sold All: 12 Reduced: 17 Increased: 20 New Position: 16.

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for cancer and related diseases. The company has market cap of $355.32 million. The companyÂ’s pipeline of product candidates include Tivozanib, a vascular endothelial growth factor to optimize VEGF blockade; Ficlatuzumab, a hepatocyte growth factor (HGF) inhibitory antibody, which has completed Phase II trial that inhibits the activity of the HGF/c-Met pathway; and AV-203, an anti-ErbB3 specific monoclonal antibody that has completed a Phase I dose escalation study. It currently has negative earnings. The Company’s development programs also comprise AV-380, a humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and the AV-353 platform for the potential treatment of pulmonary arterial hypertension.

The stock increased 4.30% or $0.095 during the last trading session, reaching $2.305. About 1.01M shares traded. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) has risen 182.80% since June 18, 2017 and is uptrending. It has outperformed by 170.23% the S&P500.

Analysts await AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) to report earnings on August, 8. They expect $-0.06 EPS, up 25.00 % or $0.02 from last year’s $-0.08 per share. After $-0.08 actual EPS reported by AVEO Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -25.00 % EPS growth.

Deer Vi & Co. Llc holds 100% of its portfolio in AVEO Pharmaceuticals, Inc. for 675,242 shares. Nea Management Company Llc owns 16.36 million shares or 2.11% of their US portfolio. Moreover, New Leaf Venture Partners L.L.C. has 1.51% invested in the company for 964,520 shares. The Massachusetts-based Ra Capital Management Llc has invested 1.12% in the stock. 683 Capital Management Llc, a New York-based fund reported 2.50 million shares.

Since January 1, 0001, it had 40 insider buys, and 0 selling transactions for $27.70 million activity.

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Ratings Coverage

Ratings analysis reveals 100% of AVEO Pharma’s analysts are positive. Out of 2 Wall Street analysts rating AVEO Pharma, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $500 while the high is $5.0. The stock’s average target of $5 is 116.92% above today’s ($2.305) share price. AVEO was included in 5 notes of analysts from January 16, 2018. The rating was maintained by FBR Capital with “Buy” on Thursday, March 22. The rating was maintained by Piper Jaffray with “Buy” on Thursday, March 29. FBR Capital maintained the stock with “Buy” rating in Tuesday, January 16 report. FBR Capital maintained the stock with “Buy” rating in Tuesday, March 13 report. The firm has “Buy” rating given on Monday, February 12 by FBR Capital.

Another recent and important AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) news was published by Digitaljournal.com which published an article titled: “Deadline Upcoming in $15 Million Settlement in the AVEO Pharmaceuticals Inc (NASDAQ:AVEO) Investor Lawsuit” on May 25, 2018.

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: